精神分裂癥是一種嚴(yán)重精神疾病，患者需要長(zhǎng)期甚至終身服用抗精神病藥物。長(zhǎng)期使用非典型抗精神病藥物會(huì)引起患者葡萄糖耐量降低、血糖升高和血脂異常，使心血管疾病和2型糖尿病的發(fā)病風(fēng)險(xiǎn)增加。關(guān)注非典型抗精神病藥物誘導(dǎo)的糖脂代謝異常，闡明其發(fā)病機(jī)制，有助于早期疾病檢測(cè)和藥物個(gè)體化選擇，對(duì)預(yù)防藥物不良反應(yīng)的發(fā)生和提高臨床療效至關(guān)重要。綜述了精神分裂癥患者使用非典型抗精神病藥物引起的糖脂代謝異常及其機(jī)制的研究進(jìn)展，并提出藥物干預(yù)對(duì)策，為非典型抗精神病藥物的安全應(yīng)用提供參考。

Schizophrenia is a serious mental disease, and patients need to take antipsychotics for a long time or even for life. Long term use of atypical antipsychotics will lead to decreased glucose tolerance, increased blood sugar and abnormal blood lipids in patients with schizophrenia, and increase the risk of cardiovascular disease and type 2 diabetes. Paying attention to the abnormal glucose and lipid metabolism induced by atypical antipsychotics and clarifying its pathogenesis are helpful for early disease detection and individualized drug selection, and is very important to prevent the occurrence of adverse drug reactions and improve clinical efficacy. This article reviewed the research progress on abnormal glucose and lipid metabolism caused by atypical antipsychotics used in schizophrenia patients and its mechanism, and proposed drug intervention strategies to provide reference for the safe application of atypical antipsychotics.

R964;R977

山東省第一批藥品臨床綜合評(píng)價(jià)項(xiàng)目（2021YZ026）；濰坊市藥品臨床綜合評(píng)價(jià)項(xiàng)目（2022WFYP02）